The role of private industry in pragmatic comparative effectiveness trials

Journal of Comparative Effectiveness Research

Volumn 1, Issue 2, 2012, Pages 147-156

  Buesching, Don P ^a   Luce, Bryan R ^b   Berger, Marc L ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c OPTUM   (United States)

Author keywords

comparative; naturalistic; pragmatic; pragmatic clinical trial; private industry; trial

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BILE ACID SEQUESTRANT; DESIPRAMINE; FLUOXETINE; FLUTICASONE; GEMFIBROZIL; GENERIC DRUG; IMIPRAMINE; LITHIUM; MEVINOLIN; MONTELUKAST; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; PAROXETINE; PROBUCOL; QUETIAPINE; SERTRALINE; TERBUTALINE SULFATE; TRIAMCINOLONE ACETONIDE; VALPROATE SEMISODIUM;

ACUTE SINUSITIS; ASTHMA; BIPOLAR DISORDER; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG USE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 84877969029     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.9     Document Type: Review

References (21)

1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290(12), 1624-1632 (2003).
2. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20(8), 637-648 (1967).
3. Thorpe KE, Zwarenstein M, Oxman AD et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J. Clin. Epidemiol. 62(5), 464-475 (2009).
4. Zwarenstein M, Treweek S, Gagnier JJ et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337, a2390 (2008).
5. Luce BR, Kramer JM, Goodman SN et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann. Intern. Med. 151(3), 206-209 (2009).
6. Revicki DA, Hirschfeld RM, Ahearn EP, Weisler RH, Palmer C, Keck PE Jr. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. J. Affect. Disord. 86(2-3), 183-193 (2005).
7. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 9(2), 77-89 (2006).
8. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry 64(5), 524-531 (2003).
9. Weiss KB, Liljas B, Schoenwetter W, Schatz M, Luce BR. Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings. Clin. Ther. 26(1), 102-114 (2004).
10. Bukstein DA, Luskin AT, Bernstein A. 'Real-world' effectiveness of daily controller medicine in children with mild persistent asthma. Ann. Allergy Asthma Immunol. 90(5), 543-549 (2003).
11. Kroenke K, West SL, Swindle R et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286(23), 2947-2955 (2001).
12. Marple BF, Roberts CS, Frytak JR et al. Azithromycin extended release vs amoxicillin/ clavulanate: symptom resolution in acute sinusitis. Am. J. Otolaryngol. 31(1), 1-8 (2010).
13. Oster G, Borok GM, Menzin J et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch. Intern. Med. 156(7), 731-739 (1996).
14. Simon GE, VonKorff M, Heiligenstein JH et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275(24), 1897-1902 (1996).
15. Luce BR, Paramore LC, Parasuraman B, Liljas B, de Lissovoy G. Can managed care organizations partner with manufacturers for comparative effectiveness research? Am. J. Manag. Care. 14(3), 149-156 (2008).
16. Weiss KB, Paramore LC, Liljas B, Revicki DA, Luce BR. Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J. Asthma 42(9), 769-776 (2005).
17. Berger M, Normand SL, Anderson F et al. ISPOR Taskforce Prospective Observational Studies for Comparative Effectiveness: when seeing is believing. Presented at: ISPOR 13th Annual European Congress. Prague, Czech Republic, 6-9 November 2010.
18. Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 364(18), 1695-1707 (2011).
19. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br. J. Psychiatry Suppl. 37, 30-35 (1999).
20. Faries D, Ascher-Svanum H, Belger M. Analysis of treatment effectiveness in longitudinal observational data. J. Biopharm. Stat. 17(5), 809-826 (2007).
21. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the 'cohort multiple randomised controlled trial' design. BMJ 340, c1066 (2010).